New / Active Rapamycin Human Clinical Trials (related to Aging)

We reported earlier on a group of new human clinical trials that are funded and just starting, in this post: Rapamycin Clinical Trial Update

But - in searching on I see there are number of other small human clinical trials that are in process, that will help add to the body of knowledge of how rapamycin helps (or doesn’t) in specific age-related conditions. Its interesting to see the specific indications where medical groups see potential for rapamycin. Details below:

The PEARL study is still recruiting:

Other studies:

Rapamycin / Rapalogs and Cancer


Interest in rapamycin is accelerating exponentially…Google recently reported that in 2022, searches for rapamycin on Google have increased over 900%, Also, in 2022, a PubMed search reveals that in 2022, there have been 203 studies published with the term rapamycin in the title and 114 studies published with the term sirolimus in the title.


Study Description

As people age, muscle mass and function is lost and exercise training is an important way to reduce the effects of this and remain independent. However, not everyone can perform this exercise and the muscle responses to exercise are often reduced in older people. So far there has been no drug found to specifically treat or reduce this problem.

Muscle size depends on the balance of muscle protein breakdown and synthesis (building). This balance is regulated by multiple signals within the body, but a particular molecule - the mechanistic target of rapamycin (mTOR), is known to play an important role. For protein synthesis to build up the muscles, this pathway is needed to start the process when triggered by eating protein or exercise. Although this would suggest that mTOR activity is good, excessive levels of this signalling seem to have negative impacts on muscle maintenance with age.

In animal studies, blocking mTOR signalling has stopped the development of a number of age-related diseases and increased health-span. Drugs that block this pathway (e.g. Rapamune) reduce the stimulation of muscle protein synthesis, possibly through changing the immune system, but conversely have also been shown to increase muscle size and reduce markers of nerve supply loss. This means that drugs which block the mTOR pathway could, in older people, help to reduce the negative impacts of excessive mTOR signalling on muscle size and function.

The investigators aim to recruit 16 healthy male volunteers over 50 years old to investigate how the drug Rapamune (which blocks the mTOR pathway) affects aged human muscle both on its own and when combined with resistance exercise training

Sponsor: University of Nottingham
Collaborator: University of Oxford


Fantastic! I wish my parents lived in the UK to do this trial! I look forward to seeing the results!

Dudley Lamming and Adam Konopka discuss rapamycin and everolimus clinical trials - including the new clinical trial starting at U. Wisconsin for everolimus use for longevity: Rapamycin and Beyond: Presentation by Dudley Lamming & Adam Konopka